CN119256010A - 抗b7h3抗体及其用途 - Google Patents

抗b7h3抗体及其用途 Download PDF

Info

Publication number
CN119256010A
CN119256010A CN202380041130.7A CN202380041130A CN119256010A CN 119256010 A CN119256010 A CN 119256010A CN 202380041130 A CN202380041130 A CN 202380041130A CN 119256010 A CN119256010 A CN 119256010A
Authority
CN
China
Prior art keywords
antibody
amino acid
binding portion
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380041130.7A
Other languages
English (en)
Chinese (zh)
Inventor
荣乃燕
王卓智
李婕
顾继杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Biologics Shanghai Co Ltd
Original Assignee
Wuxi Biologics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Shanghai Co Ltd filed Critical Wuxi Biologics Shanghai Co Ltd
Publication of CN119256010A publication Critical patent/CN119256010A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380041130.7A 2022-05-18 2023-05-17 抗b7h3抗体及其用途 Pending CN119256010A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/093524 2022-05-18
CN2022093524 2022-05-18
PCT/CN2023/094711 WO2023222017A1 (en) 2022-05-18 2023-05-17 Anti-b7h3 antibody and uses thereof

Publications (1)

Publication Number Publication Date
CN119256010A true CN119256010A (zh) 2025-01-03

Family

ID=88834684

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380041130.7A Pending CN119256010A (zh) 2022-05-18 2023-05-17 抗b7h3抗体及其用途

Country Status (12)

Country Link
US (1) US20250313633A1 (enExample)
EP (1) EP4526346A1 (enExample)
JP (1) JP2025517737A (enExample)
KR (1) KR20250011957A (enExample)
CN (1) CN119256010A (enExample)
AU (1) AU2023273853A1 (enExample)
CA (1) CA3253563A1 (enExample)
CL (1) CL2024003486A1 (enExample)
IL (1) IL316510A (enExample)
MX (1) MX2024014232A (enExample)
TW (1) TW202402808A (enExample)
WO (1) WO2023222017A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118829656B (zh) * 2023-12-01 2026-04-24 苏州智核生物医药科技有限公司 B7h3结合多肽及其用途
WO2025157244A1 (zh) * 2024-01-25 2025-07-31 山东先声生物制药有限公司 抗b7h3抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AU2015306621B2 (en) * 2014-08-27 2021-05-06 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
UA125593C2 (uk) * 2017-03-31 2022-04-27 Джянгсу Хенгруй Медісін Ко., Лтд. Антитіло в7-н3, його антигензв'язуючий фрагмент та його медичне застосування
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN112851812B (zh) * 2020-06-30 2021-09-14 广州百暨基因科技有限公司 抗b7h3抗体及其应用
CN113402610B (zh) * 2021-06-09 2023-02-24 英诺湖医药(杭州)有限公司 一组b7h3单克隆抗体及其医药用途
CN113336851B (zh) * 2021-06-30 2021-12-24 徐州医科大学 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用

Also Published As

Publication number Publication date
CA3253563A1 (en) 2023-11-23
CL2024003486A1 (es) 2025-06-13
WO2023222017A1 (en) 2023-11-23
US20250313633A1 (en) 2025-10-09
JP2025517737A (ja) 2025-06-10
TW202402808A (zh) 2024-01-16
MX2024014232A (es) 2025-03-07
AU2023273853A1 (en) 2024-10-24
EP4526346A1 (en) 2025-03-26
KR20250011957A (ko) 2025-01-22
IL316510A (en) 2024-12-01

Similar Documents

Publication Publication Date Title
CN110357961B (zh) 抗人4-1bb单克隆抗体及其制备方法和用途
CN112236454B (zh) 新型抗pd-1抗体
CN113214400B (zh) 一种双特异性抗pd-l1/vegf抗体及其用途
CN114599681A (zh) 新型抗cd47抗体及其用途
JP2023511898A (ja) 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体及びその使用
JP7445752B2 (ja) 新規の抗ｐｄ－ｌ１抗体
CN114761429A (zh) 新型抗cd3/抗egfr双特异性抗体及其用途
CN110540593B (zh) 新型的抗cd3/抗cd20双特异性抗体
CN112552411B (zh) 新型抗pd-l1/抗lag-3双特异性抗体及其用途
WO2023222017A1 (en) Anti-b7h3 antibody and uses thereof
US20250026833A1 (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
TWI813951B (zh) 一種雙功能融合蛋白及其用途
JP2021501583A (ja) 抗体および使用方法
WO2023041041A1 (en) D3-binding molecules and uses thereof
CN116836290A (zh) 针对pd-l1和cd47的双特异性抗体、其制备方法及其用途
CN116601170A (zh) 抗p-钙粘蛋白抗体及其用途
HK40117348A (zh) 抗b7h3抗体及其用途
TWI847270B (zh) D3結合分子及其用途
WO2026037400A1 (en) Anti-msln antibodies and uses thereof
CN119301158A (zh) 抗her2/抗cd47分子及其用途
HK40044140B (en) Novel anti-pd-1 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40117348

Country of ref document: HK